Emerging therapeutic strategies aim to selectively target tumor-promoting CAFs by exploiting fibroblast activation protein (FAP) or other specific markers to alleviate tumor-induced immunosuppression within the TME (Ao et al., 2015). Here, FAP is linked to neoplasm.